Nu Skin Q4 rev $488.6M (-6%), adj EPS $0.37; CSO departs; FY guide $1.73-1.87B

NU SKIN ENTERPRISES, INC.

2023-FY EPS reported $0.17 revenue$1,969,131,000

Q4 revenue $488.6M (-6% YoY), adj EPS $0.37 vs $0.89; reported EPS $0.15.
FY2023 revenue $1.97B (-12%); adj EPS $1.85 after inventory write-off charges.
FY2024 guidance: rev $1.73-1.87B, adj EPS $0.95-1.35; Q1 rev $400-435M, adj EPS $0.00-0.10.
Quarterly dividend set at $0.06/share; record Feb 26, payable Mar 6, 2024.
CSO Joseph Chang departs Mar 30; will transition to Scientific Advisory Board; role no longer executive.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph Chang

Chief Scientific Officer

NUS · NU SKIN ENTERPRISES, INC.

Effective: 2024-03-30
Filed: February 14, 2024, 6:59 PM ET

Joseph Chang informed Nu Skin Enterprises, Inc. (the “Company”) that he will be stepping down from his role as Chief Scientific Officer as of March 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NU SKIN ENTERPRISES, INC. reported Full-year 2024 results: revenue $1.73 to $1.87 billion, EPS $0.75 to $1.15 or $0.95 to $1.35 non-GAAP. Guidance reaffirmed.

Period: Full-year 2024
Revenue: $1.73 to $1.87 billion
EPS: $0.75 to $1.15 or $0.95 to $1.35 non-GAAP
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

2024 Revenue $1.73 to $1.87 billion; (12)% to (5)% • Approximately (1)% FX impact 2024 EPS $0.75 to $1.15 or $0.95 to $1.35 non-GAAP

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NU SKIN ENTERPRISES, INC. reported Q1 2024 results: revenue $400 to $435 million, EPS $(0.07) to $0.03. Guidance reaffirmed.

Period: Q1 2024
Revenue: $400 to $435 million
EPS: $(0.07) to $0.03
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Q1 2024 Revenue $400 to $435 million; (17)% to (10)% • Approximately (3) to (2)% FX impact Q1 2024 EPS $(0.07) to $0.03 or $0.00 to $0.10 non-GAAP

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NU SKIN ENTERPRISES, INC. reported financial results for the three-month and annual periods ended December 31, 2023.

Period: the three-month and annual periods ended December 31, 2023
Result: reported results

Exact text from the filing

On February 14, 2024, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month and annual periods ended December 31, 2023, and certain other information.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Chang departed as Chief Scientific Officer at NU SKIN ENTERPRISES, INC..

Action: stepping down
Role: Chief Scientific Officer

Exact text from the filing

Joseph Chang informed Nu Skin Enterprises, Inc. (the “Company”) that he will be stepping down from his role as Chief Scientific Officer as of March 30, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

NU SKIN ENTERPRISES, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-007981

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.